Medpace (NASDAQ:MEDP) CEO Sells $394,580.92 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 668 shares of Medpace stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Medpace Price Performance

Medpace stock traded down $31.72 during mid-day trading on Thursday, hitting $544.77. 565,226 shares of the company were exchanged, compared to its average volume of 410,209. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The company has a market capitalization of $15.35 billion, a P/E ratio of 38.10, a PEG ratio of 2.21 and a beta of 1.43. The business’s 50 day simple moving average is $565.74 and its two-hundred day simple moving average is $450.35.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the company earned $3.01 earnings per share. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on MEDP shares. Barclays raised their price objective on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. TD Cowen raised their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. Finally, Cowen restated a “sell” rating on shares of Medpace in a report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $487.18.

Institutional Investors Weigh In On Medpace

Several large investors have recently made changes to their positions in MEDP. LPL Financial LLC grew its position in shares of Medpace by 2.3% during the first quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock worth $5,469,000 after buying an additional 414 shares in the last quarter. Commerce Bank boosted its stake in Medpace by 3.9% during the 1st quarter. Commerce Bank now owns 2,138 shares of the company’s stock valued at $651,000 after acquiring an additional 80 shares during the last quarter. Roberts Glore & Co. Inc. IL grew its holdings in Medpace by 2.2% during the 1st quarter. Roberts Glore & Co. Inc. IL now owns 4,251 shares of the company’s stock worth $1,295,000 after acquiring an additional 90 shares in the last quarter. Ontario Teachers Pension Plan Board increased its position in shares of Medpace by 86.6% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 14,208 shares of the company’s stock worth $4,329,000 after purchasing an additional 6,592 shares during the last quarter. Finally, Deutsche Bank AG increased its position in shares of Medpace by 11.5% in the 1st quarter. Deutsche Bank AG now owns 6,927 shares of the company’s stock worth $2,111,000 after purchasing an additional 713 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.